National Cancer Institute - Cancer.gov
This issue of Milestones highlights some of our scientific advances in FY 2021-2022.
Regular aspirin use may limit prostate cancer metastasis in African American men.
A novel therapy could prevent cancer from spreading.
New drug proves effective at shrinking von Hippel-Lindau-associated tumors.
Gut bacteria promote anti-cancer immunity by activating a key innate immune signaling pathway.
A new algorithm to SELECT the best therapy helps advance precision oncology.
CAR T-cell therapy homes in on a new target: neuroblastoma.
A novel drug combination becomes the standard of care for kidney cancer.
Surprisingly, young immune systems may support breast cancer metastasis to the brain.
Genetic analyses improve the detection and diagnosis of childhood cancers.
An unusual means of chromosome protection sheds light on cancer cell growth.
FDA approves new treatment for chronic graft-versus-host disease.
Surgeons and chemists team up to create a new hydrogel for treating mesothelioma.
Not all small cell lung cancers are the same.
Microbial transplants can lead to a better immunotherapy response.
New faculty join CCR each year to contribute to our work of making breakthrough scientific discoveries to find cures and treatments for cancer. We also recognize current faculty who have started new roles within CCR.
We are proud of our CCR awardees who represent a spectacular array of accomplishments.
Take a look at our year as told by the numbers to see a snapshot of the breakthrough scientific discoveries and important work happening at CCR.